Novartis Investigative Site

Bangkok, Bangkok 10400

0 studies enrolling now · 2 studies all time

What they study most

Psoriatic Arthritis, Rheumatoid Arthritis

Studies at this site

• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents — Completed
• Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) — Completed